Targeting TRPC1 and TRPC3 to reduce Ca2+ alterations in DMD muscles could thus represent relevant targets for alternative or complementary treatment to MD-based gene therapy. This evidence concerns the gene TRPC1 and Duchenne muscular dystrophy.